Brofaromine

This classification denotes a monoamine oxidase inhibitor with the molecular formula C14H16BrNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6WV4B8Q07H, chemically known as piperidine, 4-(7-bromo-5-methoxy-2-benzofuranyl)-, hydrochloride but generally known as brofaromine, which bears US NIH Compound Identifier 44571. Brofaromine most often comes in base and hydrochloride forms. European Medicines Agency schedules Brofaromine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05899MIG. The term BROFAROMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). BROFAROMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule brofaromine under HS 29349990 and SITC 51579. As of Q4 2014, BROFAROMINE remains the US FDA Preferred Term for this commodity. Brofaromine bears US NLM identifiers UMLS ID C0054085 and NCI Concept Code C72723. SMILES: Brc1c2oc(C3CCNCC3)cc2cc(OC)c1.